- Home
- CR vs MDGL Comparison
CR vs MDGL Comparison
Compare CR & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | MDGL |
|---|---|---|
| Founded | 1855 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.0B |
| IPO Year | 2022 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CR | MDGL |
|---|---|---|
| Price | $190.63 | $435.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $223.40 | ★ $637.92 |
| AVG Volume (30 Days) | ★ 391.4K | 344.4K |
| Earning Date | 04-27-2026 | 05-19-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | 23.96 | ★ 41.32 |
| EPS | ★ 6.26 | N/A |
| Revenue | ★ $2,305,000,000.00 | $180,133,000.00 |
| Revenue This Year | $28.11 | $58.70 |
| Revenue Next Year | $5.76 | $46.88 |
| P/E Ratio | $31.75 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $127.04 | $265.00 |
| 52 Week High | $214.31 | $615.00 |
Technical Indicators
Market Signals| Indicator | CR | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 39.32 |
| Support Level | $178.60 | $410.78 |
| Resistance Level | $191.15 | $452.22 |
| Average True Range (ATR) | 5.80 | 19.94 |
| MACD | -1.01 | 0.97 |
| Stochastic Oscillator | 3.71 | 23.73 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.